Sarah Mennenga, PhD
New York University Grossman School of Medicine
Dr. Mennenga developed a master database (from 27 CTN completed trials) to evaluate the likelihood of treatment success across different SUDs (general/mixed, tobacco, opioid, or stimulant), and utilizing different types of interventions (pharmacological vs. behavioral). This study will expand this compiled dataset to include participant-level race and ethnicity data that have been standardize across trials in order to conduct additional meta-analyses examining how the intersection of race and sex impact likelihood of treatment success and likelihood of randomization (vs. screen-fail). Analyses will evaluate whether systematic differences exist in likelihood of treatment success and likelihood of randomization into a CTN trial by race, sex, and their interaction.
All Participating Nodes: